2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-145542S
    Isovalerylcarnitine-d9 chloride 1334532-23-8 98%
    Isovalerylcarnitine-d9 chloride is the deuterium labeled Isovalerylcarnitine chloride (HY-145542). Isovalerylcarnitine chloride is a metabolite of leucine. Isovalerylcarnitine chloride can specifically activate calpain in human neutrophils. Isovalerylcarnitine chloride inhibits tumor cell proliferation and induces apoptosis. Elevated circulating levels of Isovalerylcarnitine chloride are negatively correlated with reduced lung cancer risk.
    Isovalerylcarnitine-d9 chloride
  • HY-145547S
    1-Myristoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine-d27
    1-Myristoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine-d27 (14:0 Lyso PE-d27) is the deuterium labeled 1-Myristoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine. 1-Myristoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine (14:0 Lyso PE) is a lysophospholipid with a phosphoethanolamine head and a myristoyl tail. The free amine group can conjugate with NHS active ester or coupled with carboxylic acid in the presence of a coupling agent. It also induces transient increases in intracellular calcium in PC12 cells .
    1-Myristoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine-d27
  • HY-145552A
    Azilsartan mepixetil potassium 2153458-32-1 98%
    Azilsartan mepixetil potassium (QR-01019K) is the antagonist of angiotensin II receptor. Azilsartan mepixetil potassium has stronger and longer blood pressure effect, more abvious and longer lasting heart rate lowering effect and high safety. Azilsartan mepixetil potassium has the potential for the research of hypertension, chronic heart failure and diabetic nephropathy (extracted from patent CN107400122A).
    Azilsartan mepixetil potassium
  • HY-145568A
    Feniralstat hydrochloride 2340299-00-3 98%
    Feniralstat (compound 30) hydrochloride, a pyrazole derivative, is a potent kallikrein inhibitor with an IC50 of 6.7 nM for Human plasma kallikrein (pKal). Feniralstat has no inhibition on Human KLKl, Human FXIa, Human Factor Xlla (all IC50>40 μM).
    Feniralstat hydrochloride
  • HY-145624A
    Obeversen sodium 2304711-35-9 98%
    Obeversen sodium is an antisense oligonucleotide that inhibits the synthesis of Diacylglycerol acyltransferase 2 (DGAT-2). Obeversen sodium can be used in the research of nonalcoholic fatty liver disease.
    Obeversen sodium
  • HY-145624B
    Obeversen sodium scrambled negative control 98%
    Obeversen sodium scrambled negative control is the sequence scrambled negative control of Obeversen sodium.
    Obeversen sodium scrambled negative control
  • HY-145624C
    FAM labled Obeversen sodium 98%
    FAM labled Obeversen sodiumis a FAM labled Obeversen sodium.
    FAM labled Obeversen sodium
  • HY-145624D
    Cy3 labled Obeversen sodium 98%
    Cy3 labled Obeversen sodium is a Cy3 labled Obeversen sodium.
    Cy3 labled Obeversen sodium
  • HY-146579S
    Estrone-3-glucuronide-d4 lithium 98%
    Estrone-3-glucuronide-d4 lithium is the deuterium labeled Estrone-3-glucuronide lithium. Estrone 3-glucuronide is a dominant urinary metabolite of?Estradiol?(HY-B0141) and urinary marker for female fertile window prediction. Estrone 3-glucuronide can be used in combination with luteinizing hormone in ovulation prediction kits.
    Estrone-3-glucuronide-d4 lithium
  • HY-147059R
    Dieckol (Standard) 88095-77-6
    Buclizine (dihydrochloride) (Standard) is the analytical standard of Buclizine (dihydrochloride). This product is intended for research and analytical applications. Buclizine dihydrochloride is an orally active antihistamine antiallergic compound. Buclizine dihydrochloride is a potent teratogen in the rat and shows anti-tumor activity.
    Dieckol (Standard)
  • HY-147252C
    Bezeparsen sodium scrambled negative control 98%
    Bezeparsen sodium scrambled negative control is the sequence scrambled negative control of Bezeparsen sodium.
    Bezeparsen sodium scrambled negative control
  • HY-147252D
    FAM labled Bezeparsen sodium 98%
    FAM labled Bezeparsen sodiumis a FAM labled Bezeparsen sodium.
    FAM labled Bezeparsen sodium
  • HY-147252E
    Cy3 labled Bezeparsen sodium 98%
    Cy3 labled Bezeparsen sodium is a Cy3 labled Bezeparsen sodium.
    Cy3 labled Bezeparsen sodium
  • HY-147425C
    Zerlasiran sodium scrambled negative control 98%
    Zerlasiran (SLN360) sodium scrambled negative control is the sequence scrambled negative control of Zerlasiran sodium (HY-147425A). Zerlasiran sodium is a siRNA targeting apolipoprotein A (ApoA). Zerlasiran sodium targets hepatic ApoA synthesis via RNA interference to degrade encoding mRNA. Zerlasiran sodium can be used for the research of atherosclerotic cardiovascular disease and elevated ApoA levels.
    Zerlasiran sodium scrambled negative control
  • HY-147425D
    FAM labled Zerlasiran sodium 98%
    FAM labled Zerlasiran sodium is a FAM labled Zerlasiran sodium (HY-147425A). Zerlasiran sodium is a siRNA targeting apolipoprotein A (ApoA). Zerlasiran sodium targets hepatic ApoA synthesis via RNA interference to degrade encoding mRNA. Zerlasiran sodium can be used for the research of atherosclerotic cardiovascular disease and elevated ApoA levels.
    FAM labled Zerlasiran sodium
  • HY-147425E
    Cy3 labled Zerlasiran sodium 98%
    Cy3 labled Zerlasiran sodium is a Cy3 labled Zerlasiran sodium (HY-147425A). Zerlasiran sodium is a siRNA targeting apolipoprotein A (ApoA). Zerlasiran sodium targets hepatic ApoA synthesis via RNA interference to degrade encoding mRNA. Zerlasiran sodium can be used for the research of atherosclerotic cardiovascular disease and elevated ApoA levels.
    Cy3 labled Zerlasiran sodium
  • HY-147927A
    (S)-Human enteropeptidase-IN-1 1802891-23-1
    (S)-Human enteropeptidase-IN-1 (Compound 6c) is an orally active enteropeptidase inhibitor with low systemic exposure (IC50 (initial): 26 nM; IC50 (app): 1.8 nM). (S)-Human enteropeptidase-IN-1 promotes increased fecal protein output and effectively reduces body weight in a diet-induced obese (DIO) rat model. (S)-Human enteropeptidase-IN-1 inhibits enteropeptidase via a reversible covalent mechanism and prolongs the enzyme inactivation time. (S)-Human enteropeptidase-IN-1 can be used in anti-obesity research.
    (S)-Human enteropeptidase-IN-1
  • HY-14806S1
    Teneligliptin-d4 98%
    Teneligliptin-d4 is deuterium labeled Teneligliptin. Teneligliptin (MP-513) is a potent, orally available, competitive, and long-lasting DPP-4 inhibitor. Teneligliptin competitively inhibits human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC50s of approximately 1 nM.
    Teneligliptin-d4
  • HY-148258A
    GDC-2394 sodium 2238822-08-5 98%
    GDC-2394 (Compound 20) sodium is an orally active and selective NLRP3 inhibitor, and also inhibits IL-1β with IC50s of 0.4 μM (human IL-1β) and 0.1 μM (mouse IL-1β). GDC-2394 sodium inhibits NLRP3-induced caspase-1 activity without inhibiting NLRC4-dependent inflammasome activation. GDC-2394 sodium could be used to study gouty arthritis.
    GDC-2394 sodium
  • HY-148285A
    Succinyl CoA disodium 403982-65-0 98%
    Succinyl CoA (Succinyl-coenzyme A) disodium is a pivotal intermediate metabolite in the tricarboxylic acid cycle and a key coenzyme A metabolite. Succinyl CoA disodium is biosynthesized from α-ketoglutarate or propionyl-CoA. Succinyl CoA disodium acts as a critical precursor and substrate for heme biosynthesis and gluconeogenesis. Succinyl CoA disodium insufficiency caused by cobalamin deficiency is directly linked to growth retardation, impaired heme synthesis, tissue glycine accumulation and neurological abnormalities. Succinyl-Coenzyme A sodium can be used in research on metabolic, neurological, and hematological abnormalities (such as porphyria) caused by nutritional vitamin B12 deficiency (leading to a lack of Succinyl-Coenzyme A synthesis).
    Succinyl CoA disodium
Cat. No. Product Name / Synonyms Application Reactivity